VKH
BCLI

Virtu KCG Holdings’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Virtu KCG Holdings’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,769
Closed -$177K – 2889
2017
Q1 		$177K Buy
2,769
+121
+5% +$6.3K ﹤0.01% 2489
2016
Q4 		$101K Buy
+2,648
New +$91.8K ﹤0.01% 2907
2015
Q2 		– Sell
-762
Closed -$51K – 3319
2015
Q1 		$51K Sell
762
-17
-2% -$1.07K ﹤0.01% 2822
2014
Q4 		$56K Buy
+779
New +$40.9K ﹤0.01% 3400

Other funds holding BCLI

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Virtu KCG Holdings's BCLI Position: Q2 2017 in Review

Virtu KCG Holdings sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2017, closing a stake of 2,769 shares — an estimated $177K sold.

Virtu KCG Holdings first reported a position in BCLI in Q4 2014 and held it in 4 quarters. The position peaked at $177K in Q1 2017. 26 funds tracked by Wall St. Rank hold BCLI as of Q2 2017.

  • Virtu KCG Holdings reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 2,769 BRAINSTORM CELL THERAPUTC shares in Q2 2017, an estimated $177K.
  • Virtu KCG Holdings first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 4 quarters.
  • Virtu KCG Holdings's BRAINSTORM CELL THERAPUTC position peaked at $177K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.